2006
Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial
Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. The American Journal Of Geriatric Pharmacotherapy 2006, 4: 201-209. PMID: 17062320, DOI: 10.1016/j.amjopharm.2006.08.001.Peer-Reviewed Original ResearchConceptsMajor depressive disorderComorbid major depressive disorderElderly patientsComorbid depressionEscitalopram 10Adverse eventsPilot trialBaseline Montgomery-Asberg Depression Rating Scale (MADRS) scoreMontgomery-Asberg Depression Rating Scale scoreSecondary efficacy end pointsSelective serotonin reuptake inhibitorsDepression Rating Scale scoresVeterans Affairs Medical CenterEfficacy end pointPrimary efficacy variableMedical Outcomes StudySerotonin reuptake inhibitorsShort-term administrationHAM-A scoresHamilton Rating ScaleLack of efficacyPoor treatment responseRating Scale scoresSymptoms of depressionGreater symptom severity
2001
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
Kasckow J, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste D. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal Of Geriatric Psychiatry 2001, 16: 1163-1167. PMID: 11748776, DOI: 10.1002/gps.508.Peer-Reviewed Original ResearchConceptsCitalopram augmentationScale scoreClinical Global Impression Scale scoresHamilton Depression Rating Scale scoresLarge double-blind studyDepression Rating Scale scoresAugmentation of antipsychoticsUsefulness of antidepressantsDouble-blind studySingle-blind trialMajor side effectsOlder schizophrenia patientsRating Scale scoresStable dosesElderly patientsOlder patientsAntipsychotic treatmentCitalopram groupDepressive symptomsSide effectsPatientsSchizophrenia patientsControl groupNegative symptomsAntipsychotics